Answers are grounded in this paper and cite their sources.
Early-stage detection of breast cancer remains a critical challenge for improving clinical outcomes. In this study, an experimentally label-free Raman spectroscopy approach combined with principal component analysis and supervised machine learning is reported for the detection of tumor-associated antigen signatures in serum samples. Raman spectra from early-stage and advanced breast cancer patients, as well as healthy controls, were analyzed alongside recombinant tumor-associated antigen proteins, including α -1 antitrypsin, peptidyl-prolyl cis-trans isomerase A, peroxiredoxin-2, and triosephosphate isomerase-1. Distinct spectral variations were observed in lipid-, nucleic acid-, and protein-related bands. In particular, a characteristic peak at ~ 519 ~cm⁻¹ , associated with oxidized glutathione and oxidative stress-related structural alterations, was prominently observed in early-stage breast cancer and tumor-associated antigen spectra. Machine learning models trained on principal component analysis-reduced features, including linear discriminant analysis, support vector machine, decision tree, and Naïve Bayes, demonstrated high diagnostic performance, achieving ROC-AUC values above 0.94 for early-stage breast cancer versus controls and above 0.85 for early- versus advanced-stage discrimination. Furthermore, spectral and principal component analysis comparisons revealed partial clustering overlap between early-stage breast cancer samples and tumor-associated antigen proteins, supporting the biochemical relevance of the detected signatures. This integrated spectroscopic and computational approach provides a non-invasive and accurate strategy for early breast cancer detection and stage differentiation, highlighting its potential for clinical diagnostics.
No takes yet. Share an insight, caveat, or question.
Akhtar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: